Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

GSK China Bribery Scandal Gets Sex Video Twist

Published 06/30/2014, 02:40 AM
Updated 06/30/2014, 02:45 AM
GSK China Bribery Scandal Gets Sex Video Twist

GSK China Bribery Scandal Gets Sex Video Twist

By Reuters - Glaxosmithkline (LONDON:GSK) on Sunday confirmed the existence of an intimate video recording of its former China head, Mark Reilly, which the Sunday Times reported kicked off a bribery investigation that has damaged the drugmaker's business in China.

The Sunday Times said the recording was shot without Reilly's knowledge or consent at his Shanghai flat and showed the Briton, who is separated from his wife, with his Chinese girlfriend.

It was not clear who shot the video or with what motivation. The video was emailed to top GSK executives in March 2013, the newspaper said.

A GSK spokesman confirmed the tape existed but did not comment on how it related to the alleged bribery scandal.

In July 2013, Chinese police accused Britain's biggest drugmaker of transferring as much as 3 billion yuan ($482 million) through travel agencies to bribe doctors and officials.

Reuters was not independently able to verify the link between the tape and the bribery case.

Chinese police filed corruption charges against Reilly last month. The Briton, who has been barred from leaving China, could face decades in prison. (Full Story)

Reilly has not been reachable for comment while his lawyer has declined to talk to the media. Reilly's whereabouts are unknown.

China's investigation into GSK and its scrutiny of numerous other foreign and local drugs companies have frightened foreign pharmaceutical executives so much that some fear they could be jailed and have asked their lawyers if they should temporarily leave the country.

GSK, which described the bribery allegations as "shameful" when they came to light last year, said on Sunday that it was continuing to cooperate fully with Chinese authorities on the ongoing investigation.

"The issues relating to our China business are very difficult and complicated," it added in a statement.

© Reuters/Toby Melville. The headquarters of GlaxoSmithKline, manufacturer of the cancer-treating drug Bexxar, which is being discontinued due to disappointing profits.

The bribery case has hit GSK's sales in China, as buyers have shied away from doing business with the company and GSK itself has revamped its sales and marketing model.

Bribery allegations involving GSK have come to light since then in other countries and GSK is now investigating claims that bribes were also paid to doctors in Poland, Iraq, Jordan and Lebanon.

Last month, Britain's Serious Fraud Office launched a formal criminal investigation into GSK.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.